Oncology letters 24: meta‑analysis of the efficacy and safety of sintilimab for treating advanced non‑small cell lung cancer

HIGHLIGHTS

• who: JIEJIE XIE and colleagues from the Department of Clinical Pharmacy, Sanming First Hospital, Affiliated Hospital of Fujian Medical University, Sanming, Fujian, PRChina have published the paper: ONCOLOGY LETTERS 24: Metau2011analysis of the efficacy and safety of sintilimab for treating advanced nonu2011small cell lung cancer, in the Journal: (JOURNAL) of December/24,/2018
• what: The evaluation indexes OS and PFS used the risk ratio for the statistical quantity of effect analysis; objective remission rate, overall effective rate, overall ADR incidence and drug grade 3u20115 ADR incidence were the binary variables. When P>0.1 and . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.